Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Short-term Investments (2018 - 2022)

Spero Therapeutics (SPRO) has disclosed Short-term Investments for 5 consecutive years, with $49.9 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Short-term Investments rose 29.04% year-over-year to $49.9 million, compared with a TTM value of $49.9 million through Mar 2022, up 29.04%, and an annual FY2021 reading of $33.8 million, down 18.9% over the prior year.
  • Short-term Investments was $49.9 million for Q1 2022 at Spero Therapeutics, up from $33.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $90.7 million in Q3 2018 and bottomed at $2.0 million in Q3 2020.
  • Average Short-term Investments over 5 years is $37.5 million, with a median of $33.8 million recorded in 2021.
  • The sharpest move saw Short-term Investments tumbled 95.85% in 2020, then soared 427.37% in 2021.
  • Year by year, Short-term Investments stood at $81.4 million in 2018, then crashed by 35.7% to $52.3 million in 2019, then fell by 20.3% to $41.7 million in 2020, then fell by 18.9% to $33.8 million in 2021, then soared by 47.42% to $49.9 million in 2022.
  • Business Quant data shows Short-term Investments for SPRO at $49.9 million in Q1 2022, $33.8 million in Q4 2021, and $10.6 million in Q3 2021.